Skip to main content

Table 2 Flow cytometry frequency results from COPD patients susceptible to frequent vs. infrequent exacerbations

From: Differences in systemic adaptive immunity contribute to the ‘frequent exacerbator’ COPD phenotype

Cell type FE (n = 8) Mean ± SD % / Median (IQR) % IE (n = 16) Mean freq. ± SD % / Median (IQR) % p
CD3+ 66.7 ± 12.0 77.2 ± 10.7 0.291
 CD4+ 71.2 ± 17.0 73.6 ± 14.7 0.748
  CD4+ HLA-DR+ 5.2 (2.3–7.0) 2.8 (2.3–4.9) 0.417
  CD4+ PD-1+ 29.8 ± 9.2 27.8 ± 11.5 0.652
  CD4+ Naive 37.5 ± 13.7 34.8 ± 13.3 0.651
  CD4+ Tcm 18.7 ± 4.3 23.9 ± 6.9 0.035
  CD4+ Tem 25.5 ± 11.1 25.6 ± 11.3 0.983
   CD4+ Tem PD-1+ 60.2 ± 7.6 51.6 ± 13.5 0.059
  CD4+ End 18.3 ± 4.9 15.8 ± 6.4 0.287
 CD8+ 21.0 (12.6–31.3) 19.2 (12.5–25.8) 0.787
  CD8+ HLA-DR+ 12.4 (4.2–23.4) 8.7 (6.4–20.9) 0.928
  CD8+ PD-1+ 37.9 ± 11.1 36.6 ± 13.4 0.800
  CD8+ Naïve 11.1 ± 6.5 14.3 ± 7.8 0.294
  CD8+ Tcm 15.0 (6.7–17.5) 13.0 (10.9–18.8) 0.834
  CD8+ Tem 43.9 ± 15.5 37.4 ± 8.6 0.300
   CD8+ Tem HLA-DR+ 22.7 ± 13.5 31.5 ± 13.0 0.007
  CD8+ End 27.4 ± 13.5 31.5 ± 13.0 0.488
 Treg 6.6 ± 2.0 7.6 ± 2.0 0.270
  Treg PD-1+ 39.2 ± 14.0 35.3 ± 12.7 0.521
NK 62.9 ± 18.8 57.0 ± 17.6 0.473
 NK CD56bright 2.8 ± 2.1 3.5 ± 2.2 0.594
 NK CD56dim 58.8 ± 19.8 53.4 ± 18.4 0.530
 NK CD56brightCD16dim 1.8 (1.1–4.8) 2.5 (1.4–4.4) 0.697
 NK CD56dimCD16bright 48.1 ± 20.3 45.9 ± 18.7 0.803
  NK CD56 + CD56bright 3.5 (1.6–8.9) 6.5 (2.3–9.1) 0.358
  NK CD56 + CD56dim 92.7 (87.9–98.3) 93.4 (90.6–97.6) 0.903
iNKT 1.6 (1.0–3.3) 1.2 (0.73–2.5) 0.417
γδ T 0.78 (0.34–1.4) 0.32 (0.17–0.70) 0.153
 γδ T CD56+ 30.9 ± 15.4 32.3 ± 14.7 0.834
CD4+ : CD8+ ratio 45 ± 8.0 45 ± 6.2 0.959
  1. Table shows the mean frequency (%) of cells based on their parent cell line. Significance was calculated using t test or Mann-Whitney U test as appropriate. PD-1+ cell marker for programmed cell death, End end-stage T cell, Treg regulatory T cell, NK natural killer, iNKT invariant natural killer T cell